Sensius has a proven technology with complete response rates of 77.3% of 22 patients having been treated with its technology at 12 weeks following radiotherapy.
The patients were treated with thermotherapy with curative intent in addition to radiotherapy. A complete response was present for 77.3% of the patients treated with thermotherapy. Although state-of-the-art curative radiotherapy treatments like IMRT (Intensity-Modulated Radiotherapy) and SBRT (Stereotactic Body Radiotherapy) without thermotherapy show improvements over palliative overall response rate (which is the sum of partial and complete response) of 30-37%, it comes at a price of toxicity, like severe dysphagia and bone necrosis (Ionna et al, Cancers 2021). Comparing the patient outcome against standard chemotherapy treatment, local control and local toxicity rates were comparable as reported in literature (Ward, 2018) for re-irradiation of head and neck cancers. By elimination of chemotherapy in the treatment, no systemic toxicity was measured in the patient cohort.